Pathy's Principles and Practice of Geriatric Medicine

62 62. Malcovati L, Germing U, Kuendgen A, et al. Time‐Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. J Clin Oncol. 2007; 25(23):3503–3510. doi:10.1200/JCO.2006.08.5696

63 63. Fega KR, Abel GA, Motyckova G, et al. Non‐hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015; 6(4):288–298. doi:10.1016/j.jgo.2015.05.003

64 64. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011; 38(5):635–647. doi:10.1053/j.seminoncol.2011.04.014

65 65. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony‐stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114(12):2393–2400. doi:10.1182/blood‐2009‐03‐211797

66 66. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte‐colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008; 26(21):3607–3613. doi:10.1200/JCO.2007.15.4906

67 67. Buckstein R, Balleari E, Wells R, et al. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems. Am J Hematol. 2017; 92(10):1037–1046. doi:10.1002/ajh.24842

68 68. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010; 28(33):4996–5010. doi:10.1200/JCO.2010.29.2201

69 69. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116(20):4045–4059. doi:10.1182/blood‐2010‐08‐300541

70 70. Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo‐controlled trial of darbepoetin alfa in patients with anemia and lower‐risk myelodysplastic syndromes. Leukemia. 2017; 31(9):1944–1950. doi:10.1038/leu.2017.192

71 71. Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo‐controlled study assessing the efficacy and safety of epoetin‐α in anemic patients with low‐risk MDS. Leukemia. 2018; 32(12):2648–2658. doi:10.1038/s41375‐018‐0118‐9

72 72. Hellström‐Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89(1):67–71. doi:10.1111/j.1365‐2141.1995.tb08909.x

73 73. Hellström‐Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: Significant effects on quality of life. Br J Haematol. 2003; 120(6):1037–1046. doi:10.1046/j.1365‐2141.2003.04153.x

74 74. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‐CSF: The GFM experience. Blood. 2008; 111(2):574–582. doi:10.1182/blood‐2007‐06‐096370

75 75. J.R. W, Y.C. U, J.A. J, et al. Randomized, double‐blind, placebo‐controlled trial of erythropoietin in non‐small‐cell lung cancer with disease‐related anemia. J Clin Oncol. 2007; 25(9):1027–1032. doi:10.1200/JCO.2006.07.1514 LK ‐ http://WT3CF4ET2L.search.serialssolutions.com?sid=EMBASE&issn=0732183X&id=doi:10.1200%2FJCO.2006.07.1514&atitle=Randomized%2C+double‐blind%2C+placebo‐controlled+trial+of+erythropoietin+in+non‐small‐cell+lung+cancer+with+disease‐related+anemia&stitle=J.+Clin.+Oncol.&title=Journal+of+Clinical+Oncology&volume=25&issue=9&spage=1027&epage=1032&aulast=Wright&aufirst=James+R.&auinit=J.R.&aufull=Wright+J.R.&coden=JCOND&isbn=&pages=1027‐1032&date=2007&auinit1=J&auinitm=R

76 76. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study. J Clin Oncol. 2008; 26(7):1040–1050. doi:10.1200/JCO.2007.14.2885

77 77. Jädersten M, Montgomery SM, Dybedal I, Porwit‐MacDonald A, Hellström‐Lindberg E. Long‐term outcome of treatment of anemia in MDS with erythropoietin and G‐CSF. Blood. 2005; 106(3):803–811. doi:10.1182/blood‐2004‐10‐3872

78 78. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47–61. doi:10.1182/asheducation‐2001.1.47

79 79. Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol. 2003; 509:91–125. doi:10.1007/978‐1‐4615‐0593‐8_6

80 80. Messa E, Cilloni D, Saglio G. Iron Chelation Therapy in Myelodysplastic Syndromes. Adv Hematol. 2010; 2010. doi:10.1155/2010/756289

81 81. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron‐overloaded patients with transfusion‐dependent myelodysplastic syndromes: Results from the large 1‐year EPIC study. Leuk Res. 2010; 34(9):1143–1150. doi:10.1016/j.leukres.2010.03.009

82 82. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008; 83(11):858–861. doi:10.1002/ajh.21269

83 83. Suzuki T, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol. 2008; 88(1):30–35. doi:10.1007/s12185‐008‐0119‐y

84 84. Mittelman M, Lugassy G, Merkel D, et al. Iron chelation therapy in patients with myelodysplastic syndromes: Consensus conference guidelines. Isr Med Assoc J. 2008; 10(5):374–376.

85 85. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003; 120(2):187–200. doi:10.1046/j.1365‐2141.2003.03907.x

86 86. Slichter SJ. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337(26):1861–1869. doi:10.1056/NEJM199712253372601

87 87. Syndromes ICSG for rHuEpo in M, Ferrini PR, Grossi A, et al. A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes. Br J Haematol. 1998; 103(4):1070–1074.

88 88. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion‐dependent patients with Low‐/Intermediate‐1‐risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765–3776. doi:10.1182/blood‐2011‐01‐330126

89 89. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion‐dependent patients with lower‐risk non‐del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis‐stimulating agents. J Clin Oncol. 2016; 34(25):2988–2996. doi:10.1200/JCO.2015.66.0118

90 90. Schiffer CA, Miller K, Larson RA, et al. A double‐blind, placebo‐controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000; 95(8):2530–2535. doi:10.1182/blood.v95.8.2530.008k31_2530_2535

91 91. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double‐blind, placebo‐controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999; 94(11):3694–3701.